The Week in Review: Xizang Haisco Pharma Completes $127 Million IPO

Xizang Haisco Pharma, a Tibetan TCM company, staged a $127 million IPO in Shenzhen; Sanjiu Medical and Pharma expects to spend between $94.7 and $110.5 million to buy Shandong Shunfeng Pharma; Da An Gene formed a diagnostics JV with Life Technologies of San Diego; Jiangsu Kanion Pharma transferred the global ex-China rights for three oncology drug candidates to NewGen Therapeutics of California; ShangPharma reached the first milestone in its mAb partnership with Jiangsu Hengrui Medicine; Quintiles opened a back office center in Dalian, a northeast China city; Novartis received SFDA approval for Lucentis, a treatment for wet AMD, and will launch its diabetes drug, Galvus, in China; Xiamen Innovax Biotech was granted SFDA approval for a hepatitis E vaccine; and Drs. Zhen-Yi Wang and Zhu Chen were awarded a prestigious US prize for their groundbreaking work with a leukemia sub-type. More details…. Stock Symbols: (SHE: 002653) (SHE: 000999) (SHE: 002030) (NSDQ: LIFE) (SHA: 600557) (NYSE: SHP) (NYSE: NVS) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});